{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:53:58Z","timestamp":1770908038163,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":3371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1093\/annonc\/mdq420","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T07:47:43Z","timestamp":1287474463000},"page":"vii345-vii348","source":"Crossref","is-referenced-by-count":72,"special_numbering":"S7","title":["Advances in the treatment of metastatic or unresectable biliary tract cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"J.W.","family":"Valle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq420_bb0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2007-1007302","article-title":"Recent advances in the management of cholangiocarcinomas","volume":"14","author":"Vauthey","year":"1994","journal-title":"Semin Liver Dis"},{"key":"10.1093\/annonc\/mdq420_bb0015","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0168-8278(02)00297-0","article-title":"Changing international trends in mortality rates for liver, biliary and pancreatic tumours","volume":"37","author":"Khan","year":"2002","journal-title":"J Hepatol"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdq420_bb0020","first-page":"vi1","article-title":"Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document","volume":"51","author":"Khan","year":"2002","journal-title":"Gut"},{"key":"10.1093\/annonc\/mdq420_bb0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq420_bb0030","first-page":"2020","article-title":"Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial","volume":"45","author":"Takada","year":"1998","journal-title":"Hepatogastroenterology"},{"issue":"Suppl","key":"10.1093\/annonc\/mdq420_bb0035","article-title":"A randomized controlled trial (RCT) comparing best supportive care (BSC), 5-FU plus folinic acid (FUFA) and, gemcitabine plus oxaliplatin (GemOx) in management of unresectable gallbladder cancer (GBC)","volume":"27","author":"Dwary","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq420_bb0040","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.bjc.6602576","article-title":"Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer","volume":"92","author":"Rao","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq420_bb0045","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study \u2013 the UK ABC-01 study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq420_bb0050","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdq420_bb0055","article-title":"A randomized study of gemcitabine\/cisplatin versus single-agent gemcitabine in patients with biliary cancer","volume":"27","author":"Furuse","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq420_bb0060","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq420_bb0065","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andre","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq420_bb0070","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/annonc\/mdh172","article-title":"Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience","volume":"15","author":"Knox","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq420_bb0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br J Cancer"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdq420_bb0080","article-title":"A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial","volume":"27","author":"Malka","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq420_bb0085","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2005.03.040","volume":"128","author":"Lazaridis","year":"2005","journal-title":"Cholangiocarcinoma. Gastroenterology"},{"key":"10.1093\/annonc\/mdq420_bb0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1386-6346(00)00117-0","article-title":"Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines","volume":"20","author":"Ogasawara","year":"2001","journal-title":"Hepatol Res"},{"key":"10.1093\/annonc\/mdq420_bb0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2006.09.011","article-title":"Molecular pathology of biliary tract cancers","volume":"250","author":"Fava","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdq420_bb0100","first-page":"1083","article-title":"Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells","volume":"63","author":"Benckert","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq420_bb0105","first-page":"525","article-title":"Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1\/2, thrombospondin-1 and clinicopathological significance","volume":"15","author":"Tang","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1093\/annonc\/mdq420_bb0110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq420_bb0115","article-title":"A multi-institutional study of AZD6244 (ARRY-142886) in patients with advanced biliary cancers","author":"Bekaii-Saab","year":"2009","journal-title":"AACR"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419397236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419397236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/suppl_7\/vii345\/19446834\/mdq420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T18:15:57Z","timestamp":1635790557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419397236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":22,"alternative-id":["S0923753419397236"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq420","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}